FFA
BCAX

Farther Finance Advisors’s Bicara Therapeutics BCAX Stock Holding History

Farther Finance Advisors’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.79K Buy
195
+115
+144% +$2.57K ﹤0.01% 4724
2026
Q1 		$1.64K Buy
80
+13
+19% +$224 ﹤0.01% 4961
2025
Q4 		$1.13K Buy
67
+52
+347% +$888 ﹤0.01% 4880
2025
Q3 		$237 Buy
+15
New +$168 ﹤0.01% 4688
2025
Q2 		– Sell
-16
Closed -$203 – 4685
2025
Q1 		$203 Buy
+16
New +$212 ﹤0.01% 3952

Other funds holding BCAX

GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Farther Finance Advisors's BCAX Position: Q2 2026 in Review

Farther Finance Advisors increased its Bicara Therapeutics (BCAX) stake by 144% in Q2 2026, buying an estimated $2.57K and bringing the position to 195 shares worth $5.79K. The position accounts for ﹤0.01% of the portfolio, ranked #4724.

Farther Finance Advisors first reported a position in BCAX in Q1 2025 and has held it in 5 quarters since. 5 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Farther Finance Advisors held 195 shares of Bicara Therapeutics worth $5.79K as of Q2 2026.
  • Farther Finance Advisors bought 115 Bicara Therapeutics shares in Q2 2026, an estimated $2.57K.
  • Bicara Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #4724 holding.
  • Farther Finance Advisors first reported a position in Bicara Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 5 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.